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Introduction
Enterobacter is a genus of Gram-negative, rod shaped, 
facultative anaerobic, and non-spore forming microbes of family 
Enterobacteriaceae. Enterobacter aerogenes (E. aerogenes) is well known 
opportunistic bacteria emerged as nosocomial pathogen in intensive 
care unit patients [1]. E. aerogenes was initially named as Aerobacter 
aerogenes, which was later in 1960 included in the genus Enterobacter. 
Since 1990s, E. aerogenes has been increasingly reported for resistant 
against different antimicrobials, leads to emergence of multidrug-
resistant (MDR) isolates [2]. In the last 5 years, clinical isolates of 
this species have shown natural resistant against aminopenicillins, 
often showed resistance against β-lactams antibiotics. Resistance 
mechanisms in β-lactams mostly involve enzymatic degradation 
and plasmid-mediated broad spectrum β-lactamases [3]. However, 
membrane permeability, enzyme degradation, and p-glycoprotein 
efflux pump also contribute it to enhance the level of resistance 
against carbapenems, fluoroquinolones, quinolones, tetracycline, 
and chloramphenicol [4,5]. Enterobacter species are responsible for 
high morbidity and mortality rate in recent years due to nosocomial 
infections and other health care settings [6]. Due to extended resistance 
of Gram-negative bacteria against almost all antibiotics, early initiation 
of drug therapy is required, nowadays colistin, and polymyxin 
antibiotic have been preferred as an alternative drugs against Gram-
negative pathogens [7,8]. Recent update on colistin antibiotic, a drug 
of 21st century reports it’s associated adverse effects and serious toxicity 
issues such as neurotoxicity and nephrotoxicity [9]. Despite several new 
drug discoveries of broad spectrum drugs or combination therapies, 
associated toxicities are still a serious complication. Recently, an 
alternate treatment therapy approach called biofield healing therapies 
or therapeutic touch is reported with effectively inhibiting the growth 
of bacterial cultures [10]. 
The biofield is a cumulative outcome of measurable electric and 
magnetic field, exerted by the human body [11]. It generates through 
some internal processes in the human body such as blood flow, lymph 
flow, brain functions, and heart function. The energy mainly exists 
in different forms such as potential, kinetic, magnetic, electrical, and 
nuclear energy produced from different sources. The energy field that 
surrounds and penetrates the human body is collectively defined as 
biofield and the extent of energy associated with biofield is termed 
as biofield energy. Biofield treatment includes energy therapies that 
interact with patient’s biofield and lead to improve people’s health and 
wellbeing. Mr. Trivedi’s possesses unique biofield energy, which has 
been experimentally studied in various research fields. Mr. Trivedi’s 
unique biofield treatment is also known as The Trivedi Effect®. Recently, 
Mr. Trivedi’s biofield has made significant breakthrough and results 
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Abstract
Enterobacter aerogenes (E. aerogenes) has been reported as the versatile opportunistic pathogen associated 
with the hospital infections worldwide. The aim of the study was to determine the impact of Mr. Trivedi’s biofield 
energy treatment on multidrug resistant clinical lab isolates (LSs) of E. aerogenes. The MDR isolates of E. 
aerogenes (i.e., LS 45 and LS 54) were divided into two groups, i.e., control and treated. Samples were analyzed 
for antimicrobial susceptibility pattern, minimum inhibitory concentration (MIC), biochemical study, and biotype 
number using MicroScan Walk-Away® system, on day 10 after the biofield treatment. The antimicrobial sensitivity 
assay showed 14.28% alteration out of twenty eight tested antimicrobials with respect to the control. The cefotetan 
sensitivity changed from intermediate (I) to inducible β-lactamase (IB), while piperacillin/tazobactam changed from 
resistant to IB in the treated LS 45. Improved sensitivity was reported in tetracycline, i.e., from I to susceptible (S) in 
LS 45, while chloramphenicol and tetracycline sensitivity changed from R to I in treated LS 54. Four-fold decrease in 
MIC value was reported in piperacillin/tazobactam, and two-fold decrease in cefotetan and tetracycline in the biofield 
treated LS 45 as compared to the control. MIC results showed an overall decreased MIC values in 12.50% tested 
antimicrobials such as chloramphenicol (16 µg/mL) and tetracycline (8 µg/mL) in LS 54. The biochemical study 
showed an overall 45.45% negative reaction in the tested biochemical in both the treated isolates as compared to 
the control. A change in biotype number was reported in MDR isolates (LS 45 and LS 54), while in LS 54, altered 
biotype number, i.e., 0406 0374 as compared to the control (7770 4376), with identification of the new species 
as Stenotrophomonas maltophilia with brown color as special characteristic. The study findings suggest that Mr. 
Trivedi’s biofield energy treatment on clinical MDR isolates of E. aerogenes has the significant effect on altering the 
sensitivity of antimicrobials, decreasing the MIC values, changed biochemical reactions, and biotype number.
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in living organisms and nonliving materials in a different manner. 
In life sciences, biofield treatment has altered the antimicrobial 
sensitivity pattern of pathogenic microbes. In some bacteria, genus as 
well as species was found to be altered [12-14]. Mr. Trivedi’s biofield 
treatment has also well scientifically studied in different areas such 
as materials science research [15-18], biotechnology research [19,20], 
and agriculture research [21-23]. Due to paucity of information and 
considering biofield energy as an alternate treatment approach, the 
present work was undertaken to evaluate the impact of Mr. Trivedi’s 
biofield energy treatment on antimicrobials susceptibility, biochemical 
reactions pattern, and biotype of MDR isolates of E. aerogenes.
Materials and Methods
The Two clinical MDR lab isolates (LSs) of E. aerogenes (i.e., LS 45 
and LS 54) were procured from stored stock cultures in microbiology 
lab, Hinduja hospital, Mumbai and stored as per suggested storage 
conditions until further use. The acceptability of the identification 
media and antimicrobial agents were checked prior to the study. The 
antimicrobials and biochemicals used in the study were procured from 
Sigma Aldrich, MA, USA. The antimicrobial susceptibility, biochemical 
reactions, and biotype number were evaluated on MicroScan Walk-
Away® (Dade Behring Inc., West Sacramento, CA) using Negative 
Breakpoint Combo 30 (NBPC 30) panel. The panels were allowed 
to equilibrate to room temperature prior to rehydration. All opened 
panels were used in same day. 
Inoculum preparation
The turbidity standard technique using direct inoculation of 
E. aerogenes was used. Using a sterile wooden applicator stick 
or bacteriological loop, the surface of 4-5 large or 5-10 small 
morphologically similar culture was touched for well-isolated colonies 
from an 18-24 hour non-inhibitory agar plate. Further, colonies were 
emulsified in 3 mL of inoculum water (autoclaved deionized water) to 
an equivalent of a 0.5 McFarland barium sulfate turbidity standard. 100 
μL of the standardized suspension was pipetted into 25 mL of inoculum 
water using pluronic and inverted 8-10 times.
Biofield treatment
Treated group of E. aerogenes was subjected to biofield treatment, 
keeping the control group untreated. The treatment group in sealed 
pack was handed over to Mr. Trivedi for biofield treatment under 
laboratory condition. Mr. Trivedi provided the treatment through his 
energy transmission process to the treated groups without touching the 
samples. Treated samples were assessed for antimicrobial sensitivity, 
biochemical reactions, and biotyping as per experimental design. 
Whilst handing over these cultures to Mr. Trivedi for treatment 
purposes, optimum precautions were taken to avoid contamination. 
Evaluation of antimicrobial susceptibility assay
Antimicrobial susceptibility pattern of MDR E. aerogenes clinical 
isolates were studied using MicroScan Walk-Away® using NBPC 30 panel 
as per manufacturer’s instructions. The antimicrobial susceptibility 
pattern (S: Susceptible, I: Intermediate, R: Resistant, and IB: Inducible 
β-lactamase) and minimum inhibitory concentration (MIC) values 
were determined by observing the lowest antimicrobial concentration 
showing growth inhibition [24]. Antimicrobials used in susceptibility 
and MIC assay viz. amikacin, amoxicillin/K-clavulanate, ampicillin/
sulbactam, ampicillin, aztreonam, cefazolin, cefepime, cefotaxime, 
cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, cephalothin, 
chloramphenicol, ciprofloxacin, gatifloxacin, gentamicin, imipenem, 
levofloxacin, meropenem, moxifloxacin, norfloxacin, nitrofurantoin 
piperacillin, piperacillin/tazobactam, tetracycline, ticarcillin/K-
clavulanate, tobramycin, and trimethoprim/sulfamethoxazole.
Biochemical reaction study 
Biochemical reactions of MDR isolates of E. aerogenes were 
determined by using MicroScan Walk-Away® system in both control 
and treated groups. Biochemicals used in the study viz. acetamide, 
adonitol, arabinose, arginine, cetrimide, cephalothin, citrate, colistin, 
esculin hydrolysis, nitrofurantoin, glucose, hydrogen sulfide, indole, 
inositol, kanamycin, lysine, malonate, melibiose, nitrate, oxidation-
fermentation, galactosidase, ornithine, oxidase, penicillin, raffinose, 
rhamnose, sorbitol, sucrose, tartrate, tryptophan deaminase, 
tobramycin, urea, and Voges-Proskauer [24].
Identification by biotype number
The biotype number of MDR isolates of E. aerogenes control and 
treated sample were determined by MicroScan Walk-Away® processed 
panel data report with the help of biochemical reaction data [24].
Results 
Antimicrobial susceptibility study
The antimicrobial susceptibility of control and treated MDR 
isolates of E. aerogenes are presented in Table 1. Biofield treatment in 
LS 45, showed altered sensitivity in three antimicrobials, i.e., cefotetan 
changed from I → IB, piperacillin/tazobactam sensitivity changed 
from R → IB, and tetracycline sensitivity changed from I → S. After 
biofield treatment, sensitivity of chloramphenicol and tetracycline 
were improved from R → I in LS 54. Biofield treatment on LS 45 
showed 10.71%, while LS 54 showed 7.14% alterations among tested 
antimicrobials as compared to control (Figure 1). Overall, 14.28% 
antibiotics out of twenty-eight tested antimicrobials showed alteration 
in antimicrobial sensitivity assay with respect to control. Rest of the 
antimicrobials did not show any change in sensitivity pattern in clinical 
isolates as compared to their respective control. 
Determination of minimum inhibitory concentration (MIC)
MIC values of all antimicrobials in control and biofield treated 
clinical MDR isolates of E. aerogenes are summarized in Table 2. 
Biofield treatment in LS 45, significantly reduced the MIC values of 
cefotetan, piperacillin/tazobactam, and tetracycline antimicrobials as 
compared to control. Chloramphenicol (16 µg/mL) and tetracycline 
(8 µg/mL) also showed decreased MIC values in LS 54 with respect to 
control. Four-fold decrease was observed in piperacillin/tazobactam (≤ 
16 µg/mL) and two-fold decreases were found in cefotetan (≤ 16 µg/
mL) and tetracycline (≤ 4 µg/mL). Biofield treatment showed alteration 
in three antimicrobials MIC value in LS 45 (9.37%), while MIC of two 
antimicrobials showed alteration in LS 54 (6.25%) with respect to 
control (Figure 1). An overall 12.50% among tested antimicrobials out 
of thirty two showed alteration in MIC values. Rest of the antimicrobials 
did not show any alteration in MIC values after biofield treatment in 
both clinical isolates of E. aerogenes.
Biochemical and biotype number study
Biochemical study results of control and biofield treated isolates 
of E. aerogenes are summarized in Table 3. Results showed an overall 
45.45% reverse reactions in tested biochemical as compared to control. 
LS 45 showed only 3.03% alteration, i.e., negative reaction (positive 
‘+’ to negative ‘-’) in arginine, while in LS 54, showed 42.42% negative 
reaction after biofield treatment as compared to control (Figure 1). 
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Adonitol, arabinose, esculin hydrolysis, glucose, inositol, melibiose, 
oxidation-fermentation, galactosidase, raffinose, rhamnose, sorbitol, 
sucrose, tartrate, and Voges-Proskauer showed negative reaction after 
biofield treatment in LS 54. Rest of the biochemicals did not show any 
change in reaction with respect to the control. 
Based on the above results of biochemical reactions, significant 
alteration in biotype number was observed in both isolates after biofield 
treatment as compared to control. In LS 45, changed biotype was found 
as 7774 5372, as compared to control biotype number 7774 7372. New 
organism was identified as Stenotrophomonas maltophilia with brown 
color as special characteristics along with altered biotype number 0406 
0374 after biofield treatment in LS 54 on day 10 with respect to control, 
7770 4376 (Table 4). 
Discussion
Biofield treatment was reported as an alternative therapy in medical 
health care practice [25]. This experimental was designed to demonstrate 
the influence of biofield treatment on MDR isolates of E. aerogenes for 
its susceptibility pattern, biochemical reaction and biotype number. 
The emergence of MDR isolates of E. aerogenes harbored a global 
health problem and an emerging Gram-negative MDROs commonly 
associated with severe systemic and hospital acquired infections in 
human. MDR is an unavoidable natural phenomenon which results 
due to continuous discovery of newer drugs. This experiment showed 
that, biofield treatment induces changes in susceptibility pattern 
of antimicrobials such as chloramphenicol, tetracycline, cefotetan, 
piperacillin/tazobactam, and tetracycline as compared to control. 
Tetracycline and chloramphenicol showed increased sensitivity after 
biofield treatment in LS 54 as compared to control. Clinical isolates of 
E. aerogenes have a broad ability to develop antimicrobial resistance 
S. No. Antimicrobial
LS 45 LS 54
C T C T
1. Amikacin >32 >32 >32 >32
2. Amoxicillin/k-clavulanate >16/8 >16/8 >16/8 >16/8
3. Ampicillin/sulbactam >16/8 >16/8 >16/8 >16/8
4. Ampicillin >16 >16 >16 >16
5. Aztreonam >16 >16 >16 >16
6. Cefazolin >16 >16 >16 >16
7. Cefepime >16 >16 >16 >16
8. Cefotaxime >32 >32 >32 >32
9. Cefotetan 32 ≤ 16 >32 >32
10. Cefoxitin >16 >16 >16 >16
11. Ceftazidime >16 >16 >16 >16
12. Ceftriaxone >32 >32 >32 >32
13. Cefuroxime >16 >16 >16 >16
14. Cephalothin >16 >16 >16 >16
15. Chloramphenicol 16 16 >16 16
16. Ciprofloxacin >2 >2 >2 >2
17. ESBL-a Scrn >4 >4 >4 >4
18. ESBL-b Scrn >1 >1 >1 >1
19. Gatifloxacin 4 4 >4 >4
20. Gentamicin >8 >8 >8 >8
21. Imipenem ≤ 4 ≤ 4 >8 >8
22. Levofloxacin >4 >4 >4 >4
23. Meropenem ≤ 4 ≤ 4 >8 >8
24. Moxifloxacin >4 >4 >4 >4
25. Nitrofurantoin >64 >64 >64 >64
26. Norfloxacin >8 >8 >8 >8
27. Piperacillin >64 >64 >64 -
28. Piperacillin/tazobactam >64 ≤ 16 >64 -
29. Tetracycline 8 ≤ 4 >8 8
30. Ticarcillin/k-clavulanate >64 >64 >64 >64
31. Tobramycin >8 >8 >8 >8
32. Trimethoprim/sulfamethoxazole >2/38 >2/38 >2/38 >2/38
MIC values are presented in µg/mL; -: Not Reported; ESBL-a, b Scrn: Extended-
Spectrum β- Lactamase screen
Table 2: Effect of biofield treatment on Enterobacter aerogenes to MIC value of 
tested antimicrobials.
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Figure 1: Antibiogram of control and biofield treated multidrug-resistant isolates 
of Enterobacter aerogenes. 
S. No. Antimicrobial
LS 45 LS 54
C T C T
1 Amikacin R R R R
2 Amoxicillin/k-clavulanate R R R -
3 Ampicillin/sulbactam R R R -
4 Ampicillin R R R -
5 Aztreonam R R R R
6 Cefazolin R R R -
7 Cefepime R R R R
8 Cefotaxime R R R R
9 Cefotetan I IB R -
10 Cefoxitin R R R -
11 Ceftazidime R R R R
12 Ceftriaxone R R R R
13 Cefuroxime R R R -
14 Cephalothin R R R -
15 Chloramphenicol I I R I
16 Ciprofloxacin R R R R
17 Gatifloxacin I I R -
18 Gentamicin R R R R
19 Imipenem S S R R
20 Levofloxacin R R R R
21 Meropenem S S R R
22 Moxifloxacin R R R -
23 Piperacillin R R R -
24 Piperacillin/tazobactam R IB R -
25 Tetracycline I S R I
26 Ticarcillin/k-clavulanate R R R R
27 Tobramycin R R R R
28 Trimethoprim/sulfamethoxazole R R R R
C: Control; T: Treatment; LS: Lab Isolate; S: Susceptible; I: Intermediate; R: Re-
sistant; 
IB: Inducible β-lactamase; -: Not reported
Table 1: Effect of biofield treatment on Enterobacter aerogenes to antimicrobial 
susceptibility.
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[26]. Natural resistance against chloramphenicol may be mediated 
either enzymatically through acetylation of the drug or mechanically via 
active drug efflux [27]. However, efflux mechanism is generally involved 
to expel the antimicrobials such as tetracycline, fluoroquinolones and 
chloramphenicol in Enterobacter sp. [28]. Biofield treatment on clinical 
isolates of E. aerogenes might act on enzymatic level which may change 
the mechanism of resistant against chloramphenicol and tetracycline.
A significant decreased MIC values in cefotetan, piperacillin/
tazobactam, and tetracycline antimicrobials were found after biofield 
treatment in LS 45. Chloramphenicol and tetracycline also showed 
decreased in MIC values in LS 54 along with increases antimicrobial 
sensitivity with respect to control. Increased incidence of nosocomial 
infections and broad resistance against third generation cephalosporins, 
penicillins and quinolones is a serious problem. A number of newer 
agents so called “fourth generation” antimicrobials remain effective 
for treatment [29,30]. Aminoglycosides, quinolones, trimethoprim/
sulphamethoxazole, and carbapenems displays good activity 
against Gram-negative pathogens including Enterobacter species 
[31,32]. Biofield treatment significantly decreased the MIC values of 
piperacillin/tazobactam, cefotetan, tetracycline, and chloramphenicol, 
which could suggest the action of biofield treatment on enzymatic/
genetic level which could affect the β-lactamases production that may 
lead to decrease the minimum concentration of antimicrobials required 
to inhibit the in vitro growth of E. aerogenes. 
Several phenotypic identification tests were available to differentiate 
the Enterobacter species. Experimental identification of E. aerogenes was 
performed using a series of biochemical analysis. Basic characteristics 
of Enterobacter species in biochemical reactions are presence of Voges-
Proskauer, sucrose, dextrose, glucose, lactose, rhaminose, citrate, 
lysine, ornithine decarboxylase, and motile in nature. Indole, methyl 
red and hydrogen sulphide are the negative characteristics test of 
Enterobacter species. Enterobacter aerogenes is a common contaminant 
of vegetable matter which generally forms shiny colonies with entire 
margins and convex elevation [33]. Biochemical reactions of control 
MDR isolates of E. aerogenes were well supported with literature 
data [34]. Biofield treatment showed alteration, i.e., negative reaction 
in arginine biochemical in LS 45 and adonitol, arabinose, esculin 
hydrolysis, glucose, inositol, melibiose, oxidation-fermentation, 
galactosidase, raffinose, rhamnose, sorbitol, sucrose, tartrate and 
Voges-Proskauer in LS 54 as compared to control, which is the basic 
character of Enterobacter species. Various biochemical mechanisms 
are involved in biochemical, such as enzymatic alteration involved in 
sugar transferase, isomerization of biochemical, hydrolyzing reactions, 
etc. [35]. Biofield treatment on MDR isolates of E. aerogenes may alter 
the enzymatic biochemical reactions which could show result in altered 
biochemical reactions as compared to control.
Biotyping was also performed using an automated system and 
found a significant changed in biotype number in both isolates on day 
10, and a new organism was identified as Stenotrophomonas maltophilia 
after biofield treatment in LS 54 as compared to control. The results 
of biotype number and identification of new species are based on 
the biochemical reaction pattern of control and treated samples. The 
biochemical reaction patterns of LS 54 after biofield treatment are 
well supported with literature data [36], which suggest the alteration 
in species as Stenotrophomonas maltophilia (Table 4). Based on this, 
biochemical reaction pattern, biotype number and identified species 
results are well collaborated.
In biomedical health care system, biofield therapies are very 
popularly used to enhance human wellbeing and helps in minimizing 
patient’s health [25]. Biofield treatment might act as a communication 
system using electromagnetic frequencies which will carry message 
from environment to organism and vice versa [37]. However, National 
Center for Complementary and Alternative Medicine/National 
Institute of Health (NCCAM/NIH), now defined biofield therapies 
in subcategory of energy therapies as one of the five complementary 
medicine domains [25]. In microbiology, Mr. Trivedi’s biofield 
treatment was reported on pathogenic microorganism which altered 
the phenotypic characteristics of microorganism [12-14]. Alteration 
in antimicrobials sensitivity pattern after treatment might involve cell 
receptor protein and its interactions at molecular level. Experimental 
S. No. Code Biochemical 
LS 45 LS 54
C T C T
1. ACE Acetamide - - - -
2. ADO Adonitol + + + -
3. ARA Arabinose + + + -
4. ARG Arginine + - - -
5. CET Cetrimide + + - -
6. CF8 Cephalothin + + + +
7. CIT Citrate + + + +
8. CL4 Colistin - - + +
9. ESC Esculin hydrolysis + + + -
10. FD64 Nitrofurantoin + + + +
11. GLU Glucose + + + -
12. H2S Hydrogen sulfide - - - -
13. IND Indole - - - -
14. INO Inositol + + + -
15. K4 Kanamycin + + + +
16. LYS Lysine + + + +
17. MAL Malonate + + + +
18. MEL Melibiose + + + -
19. NIT Nitrate + + + +
20. OF/G Oxidation-fermentation + + + -
21. ONPG Galactosidase + + + -
22. ORN Ornithine + + - -
23. OXI Oxidase - - - -
24. P4 Penicillin + + + +
25. RAF Raffinose + + + -
26. RHA Rhamnose + + + -
27. SOR Sorbitol + + + -
28. SUC Sucrose + + + -
29. TAR Tartrate - - + -
30. TDA Tryptophan deaminase - - - -
31. TO4 Tobramycin + + + +
32. URE Urea + + - -
33. VP Voges-Proskauer + + + -
C: Control; T: Treatment; LS: Lab Isolate; - (negative); + (positive)
Table 3: Effect of biofield treatment on Enterobacter aerogenes to the vital 
processes occurring in living organisms.
Isolate Group Biotype Number Organism Identification Special Characteristics
LS 45
C 7774 7372 Enterobacter aerogenes -
T 7774 5372 Enterobacter aerogenes -
LS 54
C 7770 4376 Enterobacter aerogenes -
T 0406 0374 Stenotrophomonas maltophilia Brown Color
C: Control; T: Treatment; LS: Lab Isolate; -: Not Reported
Table 4:  Effect of biofield treatment on bio typing of Enterobacter aerogenes.
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data showed that, biofield treatment include significant changes in 
susceptibility pattern of antimicrobials, biochemical reactions, MIC 
values, and biotype number. Biofield treatment could be an alternative 
approach to study the alteration in sensitivity pattern of MDR isolates.
Conclusions
Overall data illustrate that there has a significant impact of 
biofield treatment on antimicrobial susceptibility pattern, MIC values, 
biochemical reactions, and biotype number in clinical MDR isolates of 
E. aerogenes. Antimicrobial sensitivity assay showed 14.28% alteration, 
MIC values were significantly decreased, i.e., 12.50% among tested 
antimicrobials. Biochemical study showed an overall 45.45% altered 
reactions in tested biochemical as compared to control after biofield 
treatment in clinical isolates. On the basis of changed biotype number 
(0406 0374), new organism was identified as Stenotrophomonas 
maltophilia with brown color as special characteristics after biofield 
treatment in LS 54 as compared to control (7770 4376). Mr. Trivedi’s 
biofield energy treatment could be applied to improve the sensitivity 
of antimicrobials, which may be an alternative therapeutic healing 
approach in medical science to fight against infections due to the 
emergence of multi drug-resistant strain of E. aerogenes. 
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